BNGO — BIONANO GENOMICS INC (Healthcare >> Medical Instruments & Supplies)
BNGO FAQ
What is BNGO's ROE?
BIONANO GENOMICS INC reports a Return on Equity (ROE) of -84.34%.
What is BNGO's dividend yield?
BIONANO GENOMICS INC offers a dividend yield of 0.00%.
What is BNGO's Deepscope Quality Score?
Deepscope rates BNGO's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy BNGO?
Deepscope's AI Timing Score for BNGO is 64 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does BNGO belong to?
BIONANO GENOMICS INC is classified under the Healthcare >> Medical Instruments & Supplies sector on the NASDAQ exchange.
|
USD 1.26
Price
-0.09
(-7.14%)
Day Change
|
|
|---|
BNGO, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 70 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.26 |
| PBV / Sector |
0.39 / 4.37
GREAT
|
| Earning Per Share | -2.75 |
| PE / Sector |
N/A / 36.10
|
| PEG or PE/Growth / Sector |
N/A / -1.23
|
| Average 1M Daily Value |
0.22 M
GREAT
|
| Average 1W Daily Value |
0.21 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
54% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:37 |
| Symbol | BNGO |
| Name | BIONANO GENOMICS INC |
| Sector | Healthcare >> Medical Instruments & Supplies |
| Market | NASDAQ |
| Listed Shares | 11.48 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 14.46 / 15,809.81 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 9540 Towne Centre Drive, San Diego, CA, United States, 92121
Phone: 858 888 7600
Website: https://bionano.com
Employees: 95
Description: Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for solutions for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
ME vs SECTOR Healthcare >> Medical Instruments & Supplies
Click a bubble to view stock details · Bubble size represents market capitalization share
Google